#4054
Predictive factors of persistent thrombocytopenia after 177Lu-DOTATATE in patients with neuroendocrine tumors
Introduction:
Peptide Receptor Radionuclide Therapy (PRRT) is an effective and well tolerated treatment for advanced Neuroendocrine Tumors (NET). However, some Persistent Thrombocytopenia (PT) are described and may compromise further therapies and outcome.
Conference:
Presenting Author:
Authors:
Oziel-Taieb S,
Ferrara R,
Charrier N,
Maniry J,
Reichert T,
Keywords:
Neuroendocrine Tumor,
PRRT,
LuDOTATATE,
Thrombocytopenia,
Bone metastases,
spleen,
#3883
Immune landscape in mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN)
Introduction:
A mixed neuroendocrine-non neuroendocrine neoplasm (MiNEN) is a novel defined rare entity, made up of two morphologically distinct neoplastic components; one neuroendocrine type (NEN), and the other one non-neuroendocrine type (nNEN). Neuroendocrine differentiation of tumors is thought to influence the tumor microenvironment (TME) through the secretion of various hormones or growth factors.
Conference:
Presenting Author:
Authors:
Di Mauro A,
Ferrara G,
Iervolino D,
Scognamiglio G,
Clemente O,
Keywords:
mixed neuroendocrine,
neuroendocrine,
tumor microenvironment,
immunotherapy,
biomarker,
#3872
Mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN): Characterization of the genomic and pathological profile
Introduction:
MiNENs is a novel defined rare entity, made up of two morphologically distinct neoplastic components; one neuroendocrine type (NEN), and the other one non-neuroendocrine type (nNEN). As available data are limited, the epidemiology and pathogenesis of MiNENs remain mostly unknown.
Conference:
Presenting Author:
Authors:
Di Mauro A,
Chianese U,
Conte M,
Benedetti R,
Gerardo F,
Keywords:
neuroendocrine,
pathogenesis,
mixed neuroendocrine,
pathway,
origin,
molecular,
molecular analysis,
genomic profile,
#498
Limitations of Chromogranin A in Clinical Practice
Introduction:
Chromogranin-A (CgA) is the most accurate marker for the histological diagnosis of neuroendocrine tumors (NETs). However diagnostic usefulness of circulating CgA is controversial as several conditions, both neoplastic and non-neoplastic, may induce false positive increases of this marker.
Conference:
9th Annual ENETSConcerence (2012)
Presenting Author:
Authors:
Marotta V,
Nuzzo V,
Ferrara T,
Zuccoli A,
Del Prete M,
Keywords:
Chromogranin A,
neuroendocrine tumor,
false positive marker,
